Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes

Area of Science:

• Biochemistry
• Metabolic disorders
• Neuroscience

Background:

• Acylcarnitines are crucial for mitochondrial energy production and beta-oxidation.
• Acylcarnitines play a role in brain metabolic functions.
• Major Depressive Disorder (MDD) presents with distinct clinical subtypes.

Purpose of the Study:

• To investigate if plasma acylcarnitine profiles can biochemically differentiate three MDD subtypes: core depression (CD+), anxious depression (ANX+), and neurovegetative symptoms of melancholia (NVSM+).

Main Methods:

• Retrospective analysis of 240 depressed outpatients treated with SSRIs (citalopram/escitalopram).
• Plasma acylcarnitine levels (short-, medium-, long-chain) measured at baseline and 8 weeks using LC-MS.
• Linear mixed effects models analyzed acylcarnitine differences between phenotypes and over time.

Main Results:

• CD+ and NVSM+ showed lower short- and long-chain acylcarnitines than ANX+ at baseline and week 8.
• NVSM+ had lower medium- and long-chain acylcarnitines compared to ANX+.
• Short-chain acylcarnitines increased in CD+ and ANX+; medium- and long-chain decreased in CD+ and NVSM+ from baseline to week 8.

Conclusions:

• Acylcarnitine profiles reflect the biochemical basis of MDD clinical heterogeneity.
• Changes in acylcarnitines during SSRI treatment may indicate altered beta-oxidation and mitochondrial energetics.
• Biochemical markers like acylcarnitines, combined with clinical data, can aid in understanding MDD subtypes.